Study Comparing Legflow Versus Bare Balloon Angioplasty for Treatment of Atherosclerotic Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized multicentric study for endovascular treatment of patients with obstructive disease in the SFA (superficial femoral artery) and in the popliteal artery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

DCB Compared Stenting in Popliteal Lesions

NCT03739580

Popliteal Stenosis Popliteal Artery Occlusion Diabetes

UNKNOWN NA

Constrained Balloon Combined With Drug-coated Balloon Angioplasty for Femoropopliteal Lesion

NCT05894460

Peripheral Arterial Disease

UNKNOWN

Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity

NCT05158257

Atherosclerosis Ischemia

UNKNOWN NA

SIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries

NCT04971772

Peripheral Arterial Disease Superficial Femoral Artery Stenosis Angiopathy, Peripheral

RECRUITING

Drug Coated Ballon in Critical Limb Ischemia

NCT04737291

Drug Coated Balloon

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This interventional study will collect data about the treatment of de novo lesions or restenotic lesions. Restenotic lesions that are previously DCB (drug coated balloon) treated or in-stent restenosis are excluded in this study.

The primary objective of this randomized study is to compare the efficacy of the DCB (Legflow - Cardionovum) versus POBA for the treatment of de novo lesions or restenosis in the SFA and in the popliteal artery (segment P1 -P2) by assessing the binary restenosis rate with duplex ultrasonography at 12 months.

The secondary endpoints are the assessment of the immediate procedural outcome, distribution of Rutherford, mortality, target lesion revascularization (TLR), target extremity revascularization (TER), amputation and anklebrachial index (ABI).

For each patient enrolled, data will be collected up to 12 months after the procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug Coated Balloon (DCB) - Legflow®

Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.

Group Type EXPERIMENTAL

Legflow® balloon

Intervention Type DEVICE

Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel

Standard PTA - POBA

Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).

Group Type ACTIVE_COMPARATOR

Standard PTA

Intervention Type DEVICE

Percutaneous angioplasty performed with a standard balloon

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Legflow® balloon

Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel

Intervention Type DEVICE

Standard PTA

Percutaneous angioplasty performed with a standard balloon

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Paclitaxel eluting balloon POBA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient must sign the informed consent form prior to the index-procedure.
2. Patient must be older than 18 years.
3. Patient with Rutherford 2, 3 and 4..
4. Target lesion is an occlusion or ≥70% stenosis (visual estimate) located in SFA or popliteal artery (P1 -P2).
5. Maximum length of the target lesion is 13 cm.
6. Target lesion is TASC A, B or C.
7. Target lesion is a de novo lesion or restenotic lesion (previously POBA treated, in-stent restenosis is not allowed).
8. Inflow arteries are free from hemodynamically significant obstruction (i.e. ≥ 50% diameter stenosis). It is allowed to treat inflow lesions during the index-procedure if the result is ≤ 30% diameter stenosis (treatment with DCB or DES is not allowed). Treatment of a non-target lesion in the target vessel is allowed if the nontarget lesion is considered to be an inflow lesion.
9. Popliteal artery P3 segment (below knee popliteal artery) is free from hemodynamically significant obstruction (i.e. ≥ 50%). Treatment of a lesion in this segment is not allowed during the index-procedure.
10. At least 1 patent (\< 50% diameter stenosis) below-the-knee vessel (anterior tibial artery, posterior tibial artery or peroneal artery) till the ankle as confirmed by baseline angiography.

Exclusion Criteria

1. Patient is already included in this study (recruitment of the contralateral leg is not allowed).
2. Patient has a known intolerance to antiplatelet therapy or contrast agent.
3. Patient with known sensitivity to Paclitaxel.
4. Patient is pregnant or patient intends to become pregnant within 1 year after the index-procedure.
5. Patient takes esomeprazole or omeprazole.
6. Patient with serum creatinine \>2.0 mg/dL or renal dialysis.
7. Patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability.
8. Patient has a life expectancy \<2 years.
9. Patient with Rutherford 0, 1 , 5 and 6.
10. Patient has a target lesion that is severely calcified (grade 3 and grade 4).
11. Patient with a TASC D lesion.
12. Patient has an acute thrombus or aneurysm in the target vessel.
13. Patient has a target lesion that cannot be crossed with a guidewire.
14. Target vessel has been treated previously with a DCB or a DES.
15. Treatment of outflow lesions during the index-procedure.
16. Patients with significant disease of all 3 infrapopliteal vessels (i.e. ≥ 50% diameter stenosis in each vessel).
17. Any scheduled surgery within 3 months after the index-procedure that would necessitate the discontinuation of clopidogrel.
18. Patients with previous bypass surgery involving the SFA.
19. Patient has cirrhosis of the liver.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No